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http:WHAT THIS PAPER ADDS
This manuscript demonstrates single centre short and intermediate term results of comparison of open (OSR)
versus fenestrated endovascular (F-EVAR) repair for juxtarenal aortic aneurysms, especially with regard to the
renal function. For the ﬁrst time the outcome after both procedures is compared using Cook Zenith and Vas-
cutek Anaconda fenestrated stent grafts in the F-EVAR group.Objective: To compare the results of elective open surgical repair (OSR) and total endovascular repair of
juxtarenal aortic aneurysms (JAA), with either the Cook Zenith or the Vascutek Anaconda fenestrated stent grafts
(F-EVAR) in a university hospital setting.
Patients and methods: Between April 1999 and July 2014, of 926 patients with an abdominal aortic aneurysm, 69
were juxtarenal, where 34 had an elective OSR and 35 had F-EVAR. A post-operative rise of baseline creatinine by
>50% and/or deterioration of estimated glomerular ﬁltration rate by 25% were deﬁned as renal failure.
Results: The demographics of the patients were similar except for heart insufﬁciency, peripheral arterial disease,
and pre-existing renal artery stenosis (p< .05). Median aneurysm diameters were 57 mm (range 50e80 mm) and
56 mm (range 36e64 mm) (p ¼ .194), respectively, and the median pre-operative serum creatinine levels were
94 mmol/L (range 65e286 mmol/L) and 96 mmol/L (range 57e333 mmol/L) (p ¼ .871) with median estimated
glomerular ﬁltration rate of 68 mL/min (range 21e117 mL/min) and 70 mL/min (range 18e114 mL/min)
(p ¼ .308) in the open and endovascular groups, respectively. The technical success (OSR versus F-EVAR) was
100% versus 94.3% with complete exclusion of the aneurysms in all cases. Median procedure time was 171
versus 188 min. During median in hospital stay of 11 versus 7 days (p ¼ .05), mortality was 0 versus 2.9% and
new onset of post-operative renal insufﬁciency was detected in 26.5% versus 8.5% patients (p ¼ .05), although
with 11.8% versus 5.7% being persistent (p ¼ .428). During follow up, statistically similar new (late or persistent
post-operative) renal insufﬁciency was detected in 14.7% versus 8.8% with dialysis in 3% of patients in each
group with similar mortality within the 24 months.
Conclusions: This retrospective analysis demonstrates that OSR might be combined with more acute post-
operative renal impairment than F-EVAR for JAA, but with similar intermediate term procedure related mortality
and renal outcomes.
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Open surgical repair (OSR) of juxtarenal aortic aneurysms
(JAA) is challenging because of suprarenal, supra-superior
mesenteric artery (SMA) and even supraceliac aortic cross
clamping (CC), with temporary interruption of ﬂow through
the visceral arteries, which may cause hepatic and/orresponding author. Kerpener Str. 62, D-50937, Cologne, Germany.
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//dx.doi.org/10.1016/j.ejvs.2015.04.028mesenteric ischemia as well as renal dysfunction leading to
haemodialysis.
The cornerstone of standard endovascular aneurysm
repair (EVAR) is the requirement of a sufﬁcient proximal
landing zone below the renals for adequate and durable
sealing.1 Therefore, a more proximal landing zone is
required in cases of JAA. Thus, application of custom made
fenestrated endografts (F-EVAR) is needed, to preserve
essential visceral arteries. First introduced in 1996 by Park
and colleagues,2 F-EVAR demonstrated encouraging results
with high technical success for thoraco-abdominal aortic
aneurysms.3 According to a recent literature review, the 30
day mortality rates after F-EVAR are about 2.1% after
F-EVAR does not Impair Renal Function 433pararenal aortic aneurysm repair,4 demonstrating similar
results compared with open surgery with a mortality of
about 2.9% during JAA repair.5 On the other hand, Raux and
colleagues reported in a recent retrospective study that F-
EVAR was associated with a higher risk of 30 day peri-
operative mortality and morbidity compared with OSR for
management of complex AAA.6
In addition to the FDA/CE-approved Zenith custom made
fenestrated device (CMD) (ZFEN) (Cook Incorporated,
Bloomington, IN, USA), another CMD has recently become
available (Anaconda, Vascutek, Inchinnan, UK) with initially
promising results.7,8
The objective of the current study is to present the single
centre results of elective JAA treatment, comparing OSR
with F-EVAR with either Zenith or Anaconda fenestrated
stent grafts in a series of patients who were unsuitable for
conventional EVAR.PATIENTS AND METHODS
Prospectively collected data of patients undergoing elective
OSR or F-EVAR of JAA between April 1999 and July 2014
were analysed retrospectively. All symptomatic, mycotic,
inﬂammatory, and ruptured aneurysms were excluded. The
deﬁnition of JAA was based on the short necked AAA, if the
CC was needed above one or both renal arteries in the OSR
group. The choice for F-EVAR was based on a short
infrarenal aneurysm neck of 10 mm.
Pre-operative imaging was performed using contrast
enhanced computed tomography (CTA) with 1.5 mm sli-
ces from the neck to the groins. All patients underwent
echocardiography, lung function spirometry, or coronary
angiogram when necessary. Individual risk factors and
comorbidities included arterial hypertension (patients tak-
ing one or more antihypertensive medications), history of
myocardial infarction, coronary heart disease (current
angina and/or history of previous coronary interventions
such as angioplasty or coronary artery bypass graft), chronic
obstructive pulmonary disease, peripheral arterial disease
(history of previous interventions such as angioplasty or
bypass-surgery; current Fontaine stages I-IV and/or reduc-
tion of ankle brachial index <0.8), diabetes mellitus, heart
insufﬁciency (limitations of activity according to New York
Heart Association (NYHA) functional classiﬁcation and/or
reduction of ejection fraction <30%), and renal insufﬁciency
(current creatinine level >141 mmol/L with or without the
need of dialysis).
The patients were offered either OSR or F-EVAR and
made their choice after they were informed about the risks
and had completed a written consent form for the selected
procedure. Early in the series, renal artery stenosis was an
exclusion criterion for patients in the F-EVAR group because
of expected difﬁculties with cannulation; however, this is no
longer considered to be a contraindication. Each patient
was pre-operatively classiﬁed according to American Society
of Anesthesiologists (ASA) classiﬁcation,9 and underwent
risk evaluation according to European System for Cardiac
Operative Risk Evaluation (EuroSCORE) guidelines.10 Riskfactors and comorbidities, and their distributions in the two
groups are given in Table 1.
Stent grafts
The Cook Zenith CMD (Fig. 1) consists of a polyester graft
and a Gianturco Z-stent support skeleton. The graft is
partially constrained by diameter reducing ties, which pro-
vide the option of partial repositioning of the stent graft.
The Vascutek Anaconda CMD (Fig. 2) has a nitinol ring-stent
design. The main body is fully repositionable even after
complete unsheathing of the device and the magnet assis-
ted system provides cannulation of the contralateral gate of
the body. Prior to the procedures, an anatomical model of
the aorta was used for prototype implantation of grafts.
Procedures
OSR. All operations were performed under general anaes-
thesia with the patient in a supine position by either J.B. or
M.G. Either a transperitoneal midline or retroperitoneal
incision was selected. To mobilize the left renal vein, ligation
of the lumbar-renal, adrenal, and gonadal veins was per-
formed. When indicated, renal and visceral arteries were
isolated individually and clamped followed by aortic CC.
The distal clamps were placed either on the iliacs or the
common femoral arteries (CFA). Depending on the anat-
omy, either a tube or bifurcated Dacron graft was chosen.
The proximal anastomosis was made using an end to end
technique. The distal anastomosis was sutured either end to
end intra-abdominally or end to side to the femorals.
Mannitol (12.5 25 g) and 10 mg furosemide as well as
70e100 U/kg of heparin were given prior to CC. Renal
ischemia was deﬁned as the time from aortic CC until the
last renal artery was re-perfused.
F-EVAR. All procedures were performed under general
anaesthesia in the hybrid operating room with a ceiling
mounted angiographic C-arm system by the same surgeons
(J.B./M.G.). Initially, the Zenith stent graft was implanted
because it was the only commercially available product.
When the Anaconda stent graft became available it was also
used, with good results and offering the possibility of
repositioning and good clarity of the oriﬁces of the fenes-
trations. After that, the decision on which stent graft was
implanted was made by the main surgeon (J.B./M.G.). After
70e100 U/kg of heparin were administered, the CFAs were
punctured and cannulated either percutaneously or by open
femoral access, depending on the surgeon’s preference and
patient’s habitus. After the main body was inserted and the
fenestrations were cannulated and stented through a 20F
sheath from below, the Advanta V12 stent grafts (Atrium,
Hudson, NH, USA) were ﬂared in the proximal third by a
10 mm balloon to give a safe seal. The iliac extensions were
placed in a standard fashion. For patients with aorto-iliac
aneurysm (AIAA) and a distal landing zone in the external
iliac artery (EIA), the body of the Cook Zenith iliac side-
branched graft (ISBG) (Cook Inc., Bloomington, IN, USA)
was placed in the CIA and EIA prior to the bridging
and contralateral iliac leg as previously described.11 A
Table 1. Patients’ pre-operative demographics and comorbidities.
OSR F-EVAR p
No. of patients 34 35
Gender, M:F 26:8 30:5 .371
Age, median in y (range) 72 (57e83) 72 (60e84) .938
Aneurysm dd in mm, median (range) 57 (50e80) 56 (36e64) .194
Comorbidities
Previous MI 9 (26%) 8 (23%) .785
Hypertension 26 (76%) 30 (85%) .371
Coronary heart disease 18 (53%) 16 (45%) .633
Heart insufﬁciency 20 (59%) 2 (5%) .001a
COPD 13 (38%) 7 (20%) .117
PAD 5 (15%) 16 (45%) .008a
Smoking (current or past) 23 (67%) 27 (77%) .405
Diabetes 5 (14%) 2 (5%) .259
Chronic renal insufﬁciency 2 (6%) 4 (11%) .673
Dialysis prior to procedure 1 (3%) 0 .493
Creatinine, mmol/L, median (range) 94 (65e286) 96 (57e333) .871
eGFR, mL/min, median (range) 68 (21e117) 70 (18e114) .308
Haemoglobin, g/dL, median (range) 14.2 (9.1e18.2) 14.4 (11e17.8) .414
Renal artery stenosis 6 (17%) 0 .010a
ASA
ASA I 2 (6%) 0 .239
ASA II 13 (38%) 15 (43%) .808
ASA III 16 (47%) 18 (51%) .811
ASA IV 3 (9%) 2 (5%) .673
ASA V 0 0
ASA ¼ American Society of Anesthesiologists; COPD ¼ chronic obstructive pulmonary disease; dd ¼ diameter; eGFR ¼ estimated
glomerular ﬁltration rate; MI ¼ myocardial infarction; PAD ¼ peripheral arterial disease; y ¼ years.
a Signiﬁcant.
Figure 1. Cook Zenith fenestrated stent graft.
Figure 2. Vascutek Anaconda fenestrated stent graft.
434 R. Shahverdyan et al.completion angiogram was done to conﬁrm patency and no
endoleak. After withdrawal of the devices, the incisions
were closed in anatomical layers. If a percutaneous
approach was performed, the fascia closure technique was
applied as described.12 Cerebro-spinal ﬂuid drainage (CSF-
D) was not used routinely.
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The primary endpoint was aneurysm or procedure related
mortality, and the secondary endpoint was peri-operative
renal insufﬁciency (change in baseline serum creatinine
level as well as estimated glomerular ﬁltration rate (eGFR)
according to the Cockcroft-Gault equation13 between
before surgery, on the ﬁrst post-operative day, pre-
discharge, and last acquired value). A post-operative rise
of baseline creatinine by >50% and/or deterioration of
eGFR by 25% within 1 week were deﬁned as renal failure, as
recommended by The Kidney Disease: Improving Global
Outcomes (KDIGO) clinical practice guidelines for acute
kidney injury.14 Technical success for F-EVAR was deﬁned as
a completely excluded aneurysm without abandonment/
conversion of the procedure or intra-operative mortality,
with successful grafts to or cannulation of target vessels as
well as their patency, and no signs of type I or III endoleak.
For OSR it was patent grafts and no death.
Follow up
The pre-discharge post-operative follow up included CTA
and/or duplex ultrasound, depending on renal function, and
follow ups were then at 6 and 12 months, and annually
thereafter. Intermediate term results were analysed,
compared, and reported for up to 2 years for both groups.
Analysis
Statistical analysis was performed using the Mann-Whitney
U test, Pearson’s chi-square test, and if possible Fisher’s
exact test by SPSS Statistics Software (IBM, Armonk, NY,
USA). The estimated mortality was analysed using the
Kaplan-Meier method. Signiﬁcance was considered at p
value <.05.
RESULTS
Pre-operative data
Between April 1999 and July 2014, of 926 treated AAA, 69
patients underwent either elective OSR with suprarenal,
interrenal, supra-SMA, or supraceliac CC, or elective F-EVAR
of an asymptomatic JAA.
OSR. Of the 34 who underwent open repair, 26 were
males and eight females. Thirty-three had an atherosclerotic
AAA and one had an aneurysm after previous DeBakey IIIb
dissection.
Twenty-two patients were treated with aspirin 100 mg/
d or clopidogrel 75 mg/d and four patients took phenpro-
coumon because of an atrial ﬁbrillation.
F-EVAR. Of the 35 patients who underwent F-EVAR, there
were nine Zenith and 26 Anaconda CMD. Four patients had
an AIAA, one of whom was treated with coiling and over-
stenting of the right IIA while the other three were given
a Cook ISBG. One patient with a diameter of infrarenal aorta
of 36 mm had an aorto-iliac aneurysm, where the main
indication was an aneurysm of the left CIA of 32 mm. CSF-D
was used in ﬁve patients with higher risk of spinal cord
ischemia (SCI), based on the patients’ individualcharacteristics, such as spinal column anatomy, patent
vertebral and/or IIA or anticoagulation taken, as well as
number of fenestrations needed.
Thirty-one patients were taking antiplatelet drugs, either
aspirin 100 mg/d or clopidogrel 75 mg/d, three were taking
phenprocoumon, and one was taking the factor Xa inhibitor
rivaroxaban.
Patient demographics and relevant comorbidities did not
signiﬁcantly differ except for heart insufﬁciency (HI), pe-
ripheral arterial disease (PAD) and pre-existing renal artery
stenosis, as shown in Table 1.30 day results
OSR. All 34 procedures (32 transperitoneal, 2 retroperito-
neal) were completed successfully. In two patients a con-
tained aortic perforation was detected during the surgery.
Twenty-eight patients had an aortic tube graft, and six an
anastomosis to either CIA (3) or to CFA (3). Nine patients
had a reimplantation of, or a graft to, the renal arteries.
Renal ischemia time was a median of 30 min (range 5e
180 min). Patients spent a median of one night in the
intensive care unit (ICU). There were no deaths.
Nine patients had new onset of post-operative renal
insufﬁciency, ﬁve of which were temporary and four
persistent, with three of them having had revascularized
renal arteries. In two of the eight patients with a renal graft,
an occlusion was detected. Only one of those was revised
by thrombectomy, as the second was >24 h old with
complete loss of that kidney function.
Three patients had peri-operative cardiac events. One
had a transient ischemic attack.
F-EVAR. There were no conversions, aortic dissections, or
peripheral embolizations. The primary technical success was
94.3% (33/35). In one case there was a dislocation of the
LRA-stent with a type III endoleak. Long leg ischemia caused
by the occluding sheath meant that bridging was post-
poned. One week later a subclavian approach allowed
successful cannulation and stenting of the LRA. In the sec-
ond patient, cannulation of the celiac trunk from the
femoral approach was technically unsuccessful and was
performed 3 days later by trans-axillary access. In one case
an intra-operative rupture of the left EIA was repaired by an
iliaco-femoral Dacron graft.
In 30 cases the main body access site was the right groin,
and in ﬁve cases the left groin. Thirty-one procedures were
performed by femoral cutdown, and four percutaneously.
Three patients had four fenestrations, 11 patients had
three, 19 patients had two, and the ﬁnal two patients had
one fenestration each (Table 2).
All patients were monitored overnight post-operatively in
the intensive/intermediate care unit.
One patient with a custom made aorto-mono-iliac Zenith
stent graft with four fenestrations, followed by a femoro-
femoral cross over graft and left sided iliac occluder, had
a left sided acute limb ischemia (ALI) on the ﬁrst post-
operative day and required an additional femoro-popliteal
bypass. On the next day she had diffuse colonic ischemic
Table 2. Intra-operative results of OSR and F-EVAR.
OSR F-EVAR
Technical success 100% (34/34) 94% (33/35)
Secondary technical success 0 100% (35/35)
Procedure length, median in minutes (range) 171 (103e295) 188 (111e465)
Zenith NA 212 (132e378)
Anaconda NA 187 (111e465)
Amount of CM applied, median in mL (range) NA 159 (80e350)
Zenith NA 147.5 (80e350)
Anaconda NA 130 (94e284)
CSF-D 0 15% (5/35)
CC (OSR)
Supraceliac 15% (5/34) NA
Suprarenal 41% (14/34) NA
Interrenal 44% (15/34) NA
Prosthesis (OSR)
Aortic tube 82% (28/34) NA
Bifurcated graft 18% (6/34) NA
Renal ischemia length, median in minutes 30 (5e180) NA
Reimplantation of the renal arteries 3% (1/34) NA
Graft to the renal arteries 23% (8/34) NA
Stent grafts (F-EVAR)
Zenith NA 26% (9/35)
Anaconda NA 74% (26/35)
Stent graft repositioning (for Anaconda only) NA 42% (11/26)
No. of fenestrations (F-EVAR)
1 NA 6% (2/35)
2 NA 54% (19/35)
3 NA 32% (11/35)
4 NA 8% (3/35)
X-ray length, median in minutes (range) NA 61 (25e153)
CC ¼ cross clamping; CM ¼ contrast medium; CSF-D ¼ cerebro-spinal ﬂuid drainage; NA ¼ not applicable.
436 R. Shahverdyan et al.lesions on colonoscopy; however, with patent reno-visceral
arteries and no signs of emboli. She underwent exploratory
laparotomy, which revealed no transmural ischemia, and
died in multi-organ failure.
One patient received a left sided hemicolectomy on the
ﬁrst post-operative day because of post-operative acute
colonic ischemia, which was revealed during exploratory
laparotomy, with a successful outcome. The CTA demon-
strated patent reno-visceral arteries and no signs of
thrombi/emboli.
There were three other cases of post-operative ALI. Two
patients had iliac limb occlusions (one Zenith and one
Anaconda) on the ﬁrst and fourth days, respectively, and
one had occlusion of the CFA. All were dealt with suc-
cessfully by thrombectomy.
There were no type I or III endoleaks, but seven type II
endoleaks detected on post-operative CTA scans. No spinal
cord ischemia occurred.
Three patients had new post-operative renal insufﬁ-
ciency, one temporary and two persistent, but no patient
required dialysis.
The intra- and post-operative 30 day results are given in
Tables 2 and 3.
Target vessel patency. The total number of fenestrations
was 85, with overall target vessel patency rate of 100%.Intermediate-term results
OSR. During the 2 year follow up period, three patients died
and three were lost to follow up. All patients died for non-
procedure or aneurysm related reasons (Table 4). No
related complications were found. The survival rate was
90.3% at 1 and 2 years.
Two patients developed new renal insufﬁciency and one
patient has worsened renal insufﬁciency, requiring dialysis
for 1 year after the procedure. The median serum creatinine
level at 2 years was 102 mmol/L (range 57e734 mmol/L).
The median eGFR was 62 mL/min (range 8e98 mL/min). No
differences were detected with regard to the site of aortic
CC.
F-EVAR. No patients were lost or died during the 2 year
period. Three patients had limb occlusion at 3, 9, and 20
months, respectively, treated successfully with open sur-
gery. Of the primary seven type II endoleaks, four were
persistent and remain under surveillance. The intermediate-
term survival rate was 97.1% at 1 and 2 years (Fig. 3).
The median serum creatinine level was 97 mmol/L (range
53e380 mmol/L). Three patients had a persistent long-term
renal insufﬁciency; one of whom with pre-existing chronic
renal insufﬁciency and pre-operative creatinine level of
335.9 mmol/L required haemodialysis 1.5 years later. The
median eGFR was 70 mL/min (range 16e116) (Figs. 4 and 5).
Table 4. Post-operative long-term results after OSR and F-EVAR.
OSR F-EVAR p
Follow up in months, mean (range) 66 (2e182) 25 (2e72)
2 year mortality 10% (3/31) 3% (1/35) .335
Aneurysm/procedure related 3% (1/31) 0 .460
Long-term morbidity
Renal function
Cumulated renal insufﬁciency 15% (5/34) 9% (3/34) .709
Renal artery occlusion 0 0
New dialysis 3% (1/33) 3% (1/34) .611
Late limb graft/stent graft occlusion 0 9% (3/34) .239
Reno-visceral graft/stent occlusion 0 0
Endoleak type II NA 12% (4/34)
eGFR ¼ estimated glomerular ﬁltration rate.
Table 3. Post-operative 30 day mortality and morbidity results after OSR and F-EVAR.
OSR F-EVAR p
Hospital stay (median; range) 11 days (6e37) 7 days (3e29) .05a
Mortality 0 3% (1/35) .321
Morbidity
Renal insufﬁciency 26% (9/34) 8% (3/35) .05a
Temporary 15% (5/34) 3% (1/35) .106
Persistent until discharge 12% (4/34) 6% (2/35) .428
Occlusion of the renal graft/artery 25% (2/8) NA
Occlusion of the renal stent/artery NA 0
New onset of dialysis 0 0
Creatinine, median in mmol/L (range)
Post-operative 117 (65e357) 99 (57e309) .033a
Prior to discharge 100 (50e382) 97 (55e309) .764
eGFR, median in mL/min (range)
Post-operative 52 (14e118) 66 (19e112) .023a
Prior to discharge 65 (16e122) 69 (19e127) .494
NSTEMI 3% (1/34) 0 .493
AF 6% (2/34) 0 .239
TIA 3% (1/34) 0 .493
Pleural effusion/pneumonia 23% (8/34) 6% (2/35) .045a
ALI 0 11% (4/35) .114
Limb graft/stent graft occlusion 0 6% (2/35) .493
Peripheral artery occlusion 0 6% (2/35) .493
Colonic ischemia 0 6% (2/35) .493
Spinal cord ischemia 0 0
Endoleaks
Type I NA 0
Type II NA 20% (7/35)
Type III NA 0
Type IV NA 0
AF ¼ atrial ﬁbrillation; ALI ¼ acute limb ischemia; eGFR ¼ estimated glomerular ﬁltration rate; NSTEMI ¼ non-ST elevated myocardial
infarction; TIA ¼ transient ischemic attack.
a Signiﬁcant.
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EVAR of abdominal aortic aneurysms below the renal ar-
teries has lower immediate mortality compared with
OSR,15,16 yet long-term survival is similar.17 However, for
JAA there are no randomized trials comparing OSR with F-
EVAR.
A meta-analysis of 21 non-randomized studies on OSR for
JAA using suprarenal CC demonstrated a peri-operative
mortality of 2.9%. Moreover, the median incidence ofpost-operative renal dysfunction was 18% with new onset
of dialysis in 3.3%.5 The present results are comparable with
those data, but have no peri-operative mortality, perhaps
because of the small cohort. Although some authors
describe higher mortality and renal dysfunction rates after
supravisceral CC compared with suprarenal CC,18 the pre-
sent cohort was too small to compare this. Larger studies
showed comparable results regardless of clamping
level.19,20
Figure 3. Boxplots of pre-operative, direct post-operative, prior to discharge, and last measured creatinine levels of both open (OSR) and
endovascular (F-EVAR) groups.
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even complex aortic aneurysms can be treated by endo-
vascular repair with good short-term results. The GLOBAL-
STAR registry demonstrated primary procedural success of
99% after F-EVAR with a peri-operative mortality rate of
4.1% in 318 patients.21 Similar technical success (94.3%)
and mortality rates (2.9%) were demonstrated in the pre-
sent cohort. The long-term results of F-EVAR also demon-
strate high technical success and survival rates, although
with relatively high rates of endoleaks. A single centre 8
year experience in 100 patients treated with fenestrated
stent grafts for short necked and JAA demonstrated 94%
technical success. The estimated survival rates were 90.3%,
84.4%, and 58.5% at 1, 2, and 5 years, respectively. More-
over, the risk of renal insufﬁciency was reported in 25% of
cases.22
To the authors’ knowledge, no study has been published,
reporting a comparison of OSR and F-EVAR for JAA. Canavati
and co-workers, looking at 107 patients with short necks,
made a close comparison of infra or suprarenal clamping in
54 openly operated patients. They demonstrated higher re-
intervention rates after OSR (9.2%) with higher mortality
and morbidity rates than after F-EVAR (3.7%).23 They did
not report the survival over more than 30 days. Similarly, a
two centre retrospective study by Raux and co-workersreported only 30 day results. In contrast to the present
experience, the authors demonstrated higher rates of peri-
operative mortality and morbidity after F-EVAR than after
OSR, which was probably related to patient selection and
maybe a learning curve.6 A recent systematic review
demonstrated that post-operative short-term results of F-
EVAR and OSR do not diverge, with however, different long-
term outcomes.24
No previous direct comparison of renal function after
OSR and F-EVAR has been reported. The present results
demonstrate new immediate onset of renal insufﬁciency
after OSR in 26.5% of patients but only in 8.5% after F-
EVAR, which could be explained by the suprarenal CC in the
OSR group. However, the persistent renal insufﬁciency after
OSR was not different to that after F-EVAR. During 2 year
follow up, a slight increase was demonstrated in both
groups, but without any statistical difference.
The initial limited experience with custom made fenes-
trated Anaconda stent grafts demonstrated promising re-
sults.7,8 However, only limited numbers of patients with
short-term results are available. In contrast with the study
by Canavati only reporting on the Cook Zenith device, pa-
tients in the present study group had either Zenith or
Anaconda stent grafts. Although both stent grafts require a
learning curve for better planning and deployment, the
Figure 4. Boxplots of pre-operative, direct post-operative, prior to discharge, and last measured creatinine clearance levels of both open
(OSR) and endovascular (F-EVAR) groups.
F-EVAR does not Impair Renal Function 439main difference is that the ZFEN device has reducing ties,
which do not allow for repositioning to the same extent as
the Anaconda grafts; in particular, the ZFEN device is not
rotatable like the Anaconda device. The decision of which
stent graft should be implanted remains with the main
surgeon, taking into account global variations in availability
of the stent grafts, personal expertise, and the maximum
diameter of the aorta at the landing zone, as the Anaconda
stent grafts are limited to a diameter of 34 mm.
With the recent introduction of fenestrated “off the
shelf” devices it might be possible to perform total endo-
vascular repair of JAA in emergency or symptomatic pa-
tients. A recent study of 100 patients treated with CMD,
demonstrated that about 70% were suitable candidates for
p-Branch (Cook Inc., Bloomington, IN, USA) stent grafts.25
This was refuted somewhat by Farber, who reported that
only one quarter could have been treated appropriately.26
Preliminary prospective multicentre data with Ventana
(Endologix, Irvine, CA, USA) fenestrated grafts report tech-
nical success of 97% in 31 selected patients afterendovascular repair of JAA and PAA.27 However, long-term
results of both grafts remain to be evaluated.Limitations
The retrospective nature of the study, limited number of
patients, and implantation of different devices in the F-
EVAR group, give rise to some limitations, such as selection
bias, additional application of contrast medium during the
follow up CT-scans after F-EVAR, and missing repeated
measurements of creatinine/GFR.
CONCLUSIONS
Similar procedure related mortality and renal outcomes are
reported after OSR and F-EVAR. A longer hospital stay is
required after OSR than after F-EVAR, with, however, more
vascular re-interventions after F-EVAR. Therefore, individual
decision making regarding which procedure should be
performed and the preferences of the patient should be
taken into account.
Figure 5. Kaplan-Meier curve, demonstrating estimated long-term survival rates after OSR and F-EVAR within the follow up period of 24
months.
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